Abstract
Since its discovery in the early 1950s, aldosterone has been shown to have a major influence on renal electrolyte transport. However, it is now known that aldosterone also has important actions to promote fibrosis,1 thrombosis,2 and vascular inflammation.3 An action which has received much less consideration is the ability of aldosterone to influence angiogenesis. Angiogenesis is the formation of new blood vessels. The regulation of angiogenesis is through the release of stimulatory growth factors such as vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), and angiopoietins or inhibitory factors such as angiostatin and endostatin. Studies by Suzuki and coworkers showed that treatment with the selective mineralocorticoid receptor (MR) antagonist eplerenone (20 mg/kg/day) for 3 months in dogs subjected to progressive left ventricular dysfunction as a consequence of intracoronary microembolization substantially increased myocardial capillary density and basic FGF.4 These changes were accompanied by an improvement in cardiac ejection fraction and no change in arterial blood pressure. An increase in cardiac angiogenesis would be of particular benefit in patients postmyocardial infarction as it can provide blood flow and oxygen to support metabolism.

This publication has 9 references indexed in Scilit: